<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) June 5, 1997
------------
BOSTON LIFE SCIENCES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-6533 87-0277826
- ------------------------------------------ ------ ------------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification No.)
incorporation or organization) File No.)
31 Newbury Street, Suite 300
Boston, Massachusetts 02116
- ------------------------------------------ -------------------------
(Address of principal executive offices) Zip Code
</TABLE>
Registrant's telephone number, including area code (617) 425-0200
---------------
<PAGE>
Item 5. Other Events.
-------------
On June 5, 1997, Boston Life Sciences, Inc. announced that three separate
scientific papers pertaining to the use of Altropane(TM) in the diagnosis of
Parkinson's Disease were presented during the week at the 44th Annual Meeting of
the Society of Nuclear Medicine in San Antonio, Texas.
The first two papers detailed the results of clinical studies conducted with 15
subjects, seven of whom were healthy volunteers and eight of whom suffered from
Parkinson's Disease. The results of these studies strongly suggest that I-123
Altropane is a highly useful SPECT ligand for imaging dopamine receptors in the
human brain. Furthermore, the results of the studies underscore that the high
selectivity and rapid accumulation of Altropane in the dopamine transporters
allows for the accurate diagnosis of Parkinson's Disease in less than two hours
after injection.
The third paper detailed scientists' work with Altropane in post mortem human
brains to demonstrate its ability to bind to dopamine transporters. Altropane
binding sites were reduced by more than 80 percent in the putamen of persons who
had Parkinsons Disease thereby confirming the selectivity of Altropane for the
dopamine transporter in the human brain.
BLSI is engaged in the research and development of novel therapeutics for
cancer, autoimmune disease, and central nervous system disorders.
Item 7. Exhibits.
--------
The following Exhibits are filed as part of this report on Form 8-K:
99.1 Press Release, dated June 5, 1997.
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: June 12, 1997 By:/s/ Joseph Hernon
------------------
Joseph Hernon
Chief Financial Officer
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Page
- ----------- ----
99.1 Press Release, dated June 5, 1997 5
<PAGE>
Exhibit 99.1
SCIENTISTS PRESENT DATA ON BLSI'S ALTROPANE(TM)
--------------------------------------------
AT SOCIETY OF NUCLEAR MEDICINE MEETING IN SAN ANTONIO
-----------------------------------------------------
THREE PRESENTATIONS OUTLINE SUCCESS OF ALTROPANE
------------------------------------------------
FOR RAPID DIAGNOSIS OF PARKINSON'S DISEASE
------------------------------------------
Boston, MA, June 5, 1997 - Boston Life Sciences, Inc. (Nasdaq: BLSI) announced
today that three separate scientific papers pertaining to the use of
Altropane(TM) in the diagnosis of Parkinson's Disease were presented yesterday
at the 44th Annual Meeting of the Society of Nuclear Medicine in San Antonio,
Texas.
Dr. Alan J. Fischman, Dr. John W. Babich, and Ms. Sandy Barrow, all of
Massachusetts General Hospital and scientific collaborators of BLSI, each
presented results of recent clinical studies using Altropane, a radioimaging
agent that permits rapid SPECT scan diagnosis of Parkinson's Disease. Altropane
is being developed by Boston Life Sciences, Inc. of Boston, Massachusetts.
The first two papers presented, "Clinical Evaluation of Parkinson's Disease by
SPECT with I-123 Altropane," and "Rapid Detection of Parkinson's Disease by
SPECT with Altropane: A Selective Ligand for Dopamine Transporters," detailed
the results of clinical studies conducted with 15 subjects, seven of whom were
healthy volunteers and eight of whom suffered from Parkinson's Disease. In the
healthy volunteers, the studies demonstrated that Altropane accumulated rapidly
and selectively in the dopamine transporters in the brain and yielded excellent
quality images within an hour after injection. In patients suffering from
Parkinson's Disease, the studies showed that the accumulation of Altropane was
markedly reduced, which is consistent with a diagnosis of the disease. The
results of these studies strongly suggest that I-123 Altropane is a highly
useful SPECT ligand for imaging dopamine receptors in the human brain.
Furthermore, the results of the studies underscore that the high selectivity and
rapid accumulation of Altropane in the dopamine transporters allows for the
accurate diagnosis of Parkinson's Disease in less than two hours after
injection.
The third paper, "The SPECT Ligand Altropane Effectively Detects Parkinson's
Disease in Human Putamen," detailed scientists' work with Altropane in post
mortem human brains to demonstrate its ability to bind to dopamine transporters.
Altropane binding sites were reduced by more than 80 percent in the putamen of
persons who had Parkinsons Disease thereby confirming the selectivity of
Altropane for the dopamine transporter in the human brain.
Dr. Marc Lanser, Chief Scientific Officer of BLSI, said "We are pleased to have
the results of these important studies which conclude that Altropane has been
demonstrated as a safe and convenient agent to image the dopamine transporter
system in the brain, and therefore, can assist physicians in making an accurate
diagnosis of Parkinson's Disease."
<PAGE>
The conclusions described in the above mentioned papers, together with the
opinions expressed by Boston Life Sciences, Inc. with respect to such
conclusions, and the implications of the data referred to above, are all subject
to the uncertainties inherent in ongoing research and development. These
inherent uncertainties may necessitate the re-appraisal of the efficacy of such
products, and may impact the development schedule for such products, their
regulatory approval or lack thereof, and their ultimate commercialization.
BLSI is engaged in the research and development of novel therapeutics for
cancer, autoimmune disease, and central nervous system disorders. BLSI's
products in clinical trials or in pre-clinical development include the above
mentioned Altropane; Troponin I, an anti-angiogenesis factor for the treatment
of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system
growth factor; THERAFECTIN for the treatment of rheumatoid arthritis; and two
transcription factors to control the expression of molecules associated with
autoimmune disease and allergies.
For additional information contact:
Marc E. Lanser, M.D.
Chief Scientific Officer
617-425-0200
